We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Oncopeptides AB (ONCO) NPV

Sell:8.31 SEK Buy:8.35 SEK Change: 0.18 SEK (2.25%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:8.31 SEK
Buy:8.35 SEK
Change: 0.18 SEK (2.25%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:8.31 SEK
Buy:8.35 SEK
Change: 0.18 SEK (2.25%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Oncopeptides AB is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.

Contact details

Luntmakargatan 46, 7th floor
111 37
+46 (8) 6152040

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
614.51 million SEK
Shares in issue:
75.29 million
Stockholm Stock Exchange
Swedish Krona

Key personnel

  • Jakob Lindberg
    Chief Executive Officer
  • Annika Muskantor
    Interim Chief Financial Officer
  • Eva Nordstrom
    Chief Operating Officer, Vice President
  • Klaas Bakker
    Executive Vice President, Chief Medical Officer
  • Sofia Heigis
    Senior Vice President, Global Head Medical Affairs
  • Karolina Vilval
    General Counsel
  • Rolf Gulliksen
    Global Head of Corporate Communications
  • Fredrik Lehmann
    Head of Research and CMC

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.